The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer

Abstract

CLC Number:

R734.2

ZHAO Yan, ZHANG Ru. The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer [J]. Chinese Journal of Pharmacovigilance, 2010, 7(10): 617-619.

[1] American Cancer Society. Cancer Facts and Figures 2008 [EB/OL]. 2009-07-13[2010-06-25].http://www.cancer.org/downloads/STT/ 2008CAFFfinalsecured.pdf.
[2] World Health Organization. Fact Sheet No. 310[EB/OL]. 2009-0713[2010-06-25]. http://www.who.int/mediacentre/factsheets/fs310/en/index.html.
[3] Postmus P E, Smit E F. Chemotherapy for brain metastases of lung cancer: a Review[J]. Ann Oncol, 1999, 10(7): 753-759.
[4] Endelsohn J, Baselga J. Status of the epidermal growth factor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003,21(14): 2787-2799.
[5] Herbst R S, ShinD M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy[J]. Cancer,2002, 94(5): 1593-1611.
[6] Metro G, Finocchiaro G, Cappuzzo F. Anti-cancer therapy with EGFR inhibitors:factors of prognostic and predictive significance[J]. Ann Oncol,2006,17(suppl 2):842-845.
[7] Mok T, Wu Y-L, Thongprasert S, et al. Phase III, randomized, open-label , first-line study of gefitinib ( G ) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer(NSCLC) [J]. Ann Oncol,2008,19 (suppl 8): 1-4.
[8] Hirsch F R, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis[J].J Clin Oncol,2003,21:3798-3807.
[9] Hirsch F R, Varella-Garcia M, Bunn P A Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced nonsmall-cell lung cancer[J]. J Clin Oncol,2006, 24:5034-5042.
[10] Tsao M S, Sakurada A, Cutz J C, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome[J]. N Engl J Med,2005, 353:133-144.
[11] ShepherdF A, RodriguesP J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer[J].N Engl J Med, 2005, 353(2): 123-132.
[12] Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from “never smokers”and are associated with sensitivity of tumors to gefi tinib and erlotinib [J]. Proc Natl Acad Sci USA, 2004, 101(36):13306-13311.

[1]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[2]	XIN Lingyi, YANG Yang, ZHU Jing, HE Na, ZHANG Jingmei, WANG Hangtian, CHEN Qinhua, YANG Guangyi. Classification of anti-tumor active ingredients of Paridis Rhizoma and research progress in mechanisms of action [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 235-240.
[3]	GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo. Research progress on the animal models of idiosyncratic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
[4]	YANG Zhenzhen, CHANG Cheng, GAO Na, ZHANG Xiaolin, SONG Yinsen, LIU Ying, FAN Tianli. Molecular mechanism of luteolin for inhibiting esophageal squamous cell carcinoma based on network pharmacology and in vitro studies [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 992-1001.
[5]	HE Jia, JIN Yan, ZHAO Yuyang, ZHOU Junhui, LI Xiaolin, YUAN Yuan, FU Lu. Research progress in methods for toxicity-decreasing processing of toxic herbal traditional Chinese medicines [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1064-1070.
[6]	ZHANG Bing, SA Rina, ZHANG Xiaomeng, ZHANG Dan, LIN Zhijian, WANG Yu. Research progress in pharmacogenic cardiotoxicity [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 841-847.
[7]	LI Yamei, SHUI Rong. Research progress in tofacitinib for juvenile idiopathic arthritis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 956-960.
[8]	CHEN Linzhen, WANG Xuan, ZHANG Xiaomeng, MA Zhiqiang, LU Shan, WU Jiarui, ZHAO Chongjun, ZHANG Bing. Evaluation of hepatotoxicity of periplocin based on zebrafish model [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 742-748.
[9]	SU Yuefen, ZHENG Jingrou, GONG He, XIE Guangtong, ZHANG Jie, SAI Chunmei. Formability and mechanism of breast nodule pain-alleviating gel plaster for the treatment of breast hyperplasia [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 783-790.
[10]	LYU Peng, ZHANG Jingli, WANG Yunhong, MA Fenfen, ZHANG Yu, HUANG Yifei. Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 595-600.
[11]	YUAN Qi, WANG Yingxian, CHEN Siying, YOU Haisheng. Pharmaceutical care for a case of severe skin ulcer and corneal perforation caused by erlotinib hydrochloride tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 206-208.
[12]	LI Yanyi, ZHANG Yujie, WANG Qi, MA Shuangcheng. Research progress on the mechanism of hepatotoxicity associated with Polygonum multiflorum Thunb [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 605-609.
[13]	YIN Yuling, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, HAN Yu. Mechanism analysis and pharmacovigilance considerations of traditional Chinese medicine with "potency-toxicity" bi-directional effect of heart [J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 486-492.
[14]	BAI Siyu, CHEN Qianwen, YE Xiao, FENG Weihong, RONG Lixin, LI Chun. Network pharmacology of Tibetan medicine Ponka against influenza [J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1344-1351.
[15]	ZANG Kaihong, LIU Lili, WU Jianjun, GAO Tiantian, QIN Hongyan. Molecular mechanism of astragaloside IV in the treatment of ulcerative colitis and liver injury comorbidity based on network pharmacology [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1196-1201.

The Mechanism and Therapy Perspective of Erlotinib in Patients with Non-small Cell Lung Cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics